Allurion Technologies Inc. announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake. The global market for anti-obesity medications ? specifically of GLP-1s (glucagon-like peptide-1 receptor agonists) ?

is expected to reach $100 billion by 2030.1 Research has shown these products have significantly altered the treatment landscape and drawn further attention to the urgent need to tackle the obesity crisis. In September 2023, Allurion conducted a survey of 172 healthcare professionals to measure the potential impact of GLP-1 growth on Allurion Program awareness among Allurion patients and healthcare professionals (HCPs). The results offer valuable insights into how GLP-1s have influenced perceptions and attitudes towards medical weight-loss generally, and the role the Allurion Program can play in helping patients who are looking for a more holistic approach to weight loss.

More specifically, the survey responses highlight a belief among HCPs that the introduction of anti-obesity medications like GLP-1s have had a positive impact on raising awareness of, and generating interest in, other medical weight loss treatment options, including the Allurion Program. Key findings included: Close to one-third of HCPs said patients had tried GLP-1s before starting the Allurion Program. According to the survey results, the 3 main factors influencing their decision to begin the Allurion Program were their doctor?s recommendation; a preference for avoiding the unwanted effects of weight-loss drugs; and the ability of the Allurion Program to support rapid weight loss.

89% of HCPs believed the Allurion Program represented an ideal first-line treatment to achieve at least 10% total body weight loss in a fast and sustainable way HCPs offering GLP-1s experienced a 59% increase in patient enquiries about other medically-led weight-loss treatments 45% of HCPs believed the new anti-obesity medications had boosted awareness of, and interest in, the Allurion Program, and 34% of HCPs said they had no impact Allurion also surveyed 1,663 Allurion Program patients from 64 markets. Results generally mirrored those of the HCP research. Key findings included: Among the patients who had heard of GLP-1s (n=1014): 61% had increased awareness that diet and exercise alone were not enough to treat obesity.

64% believed that learning about GLP-1s increased their awareness of the availability of medical weight-loss treatments. 50% agreed that learning about GLP-1s increased their awareness of the Allurion Program. The remaining 50% said there was no impact on their awareness of the Allurion Program.

Among those patients who had tried GLP-1s (n=365): 85% had discontinued before starting the Allurion Program. The two main reasons for discontinuation were not achieving their weight-loss goals (36%) and negative side effects (32%). More than a quarter (n=449) of respondents had no intention of trying weight-loss drugs in the future because they did not want to take a drug or were worried about the potential negative health impacts of weight-loss drugs.